BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30341281)

  • 1. A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor.
    Hewit K; Sandilands E; Martinez RS; James D; Leung HY; Bryant DM; Shanks E; Markert EK
    Cell Death Dis; 2018 Oct; 9(11):1069. PubMed ID: 30341281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor splicing variant 7 (ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint.
    Yu B; Liu Y; Luo H; Fu J; Li Y; Shao C
    J Biol Chem; 2021; 296():100276. PubMed ID: 33428943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.
    Kregel S; Szmulewitz RZ; Vander Griend DJ
    Prostate; 2014 Nov; 74(15):1530-43. PubMed ID: 25175748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
    Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
    Hoefer J; Akbor M; Handle F; Ofer P; Puhr M; Parson W; Culig Z; Klocker H; Heidegger I
    Oncotarget; 2016 Sep; 7(37):59781-59794. PubMed ID: 27486973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
    Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles].
    Guan H; Ling ZX; Fang F; Mao LK; You ZH; Wang C; Chen SQ; Xu B; Chen M
    Zhonghua Nan Ke Xue; 2018 Feb; 24(2):116-121. PubMed ID: 30156069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Pilling A; Kim SH; Hwang C
    Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developmentally regulated GTP-binding protein 2 levels in prostate cancer cell lines impact docetaxel-induced apoptosis.
    Kim SC; Lee WH; Kim SH; Abdulkhayevich AA; Park JW; Kim YM; Moon KH; Lee SH; Park S
    Investig Clin Urol; 2021 Jul; 62(4):485-495. PubMed ID: 34190439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration.
    Obinata D; Takada S; Takayama K; Urano T; Ito A; Ashikari D; Fujiwara K; Yamada Y; Murata T; Kumagai J; Fujimura T; Ikeda K; Horie-Inoue K; Homma Y; Takahashi S; Inoue S
    Eur J Cancer; 2016 Apr; 57():39-49. PubMed ID: 26854828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.
    Chen M; Feuerstein MA; Levina E; Baghel PS; Carkner RD; Tanner MJ; Shtutman M; Vacherot F; Terry S; de la Taille A; Buttyan R
    Mol Cancer; 2010 Apr; 9():89. PubMed ID: 20420697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Crosstalk between AR3 and E2F1 in Drug Resistance in Prostate Cancer Cells.
    Xu J; Yang X; Deshmukh D; Chen H; Fang S; Qiu Y
    Cells; 2020 Apr; 9(5):. PubMed ID: 32354165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
    Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; Villa-Guzmán JC; Hernando S; Rodriguez-Vida A; González-Del-Alba A; Mellado B; Gonzalez-Billalabeitia E; Olmos D; Attard G; De Giorgi U
    Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA916798 affects growth and metastasis of androgen-dependent prostate cancer cells.
    He J; Lan X; Duan HL; Luo H; Zhou XD
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4477-4487. PubMed ID: 30058677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.